Pioneers in Clinical Research
Our research has resulted in more effective treatment modalities and cure rates that are higher than the national averages.
Since 1985, the physicians and researchers at the WCRF have been at the forefront of pioneering clinical research, aimed at enhancing cure rates among women diagnosed with breast, ovarian, uterine, and cervical cancers. WCRF actively engages in designing, conducting, and disseminating groundbreaking research focused on cutting-edge medical treatments.
Furthermore, WCRF serves as a vital hub for both foundational and applied research, as well as education, pertaining to the latest advancements in the treatment of breast and gynecologic cancers. In addition to conducting and publishing original research, the WCRF, provides valuable clinical information to physicians and patients alike.
Clinical trial research evaluates the newest medication and other treatment methods to determine if these new approaches can increase cure rates. These new treatment trials require a team of great doctors, research analysts, and coordinators, to safely administer these new treatments and assess efficacy. This is the final step in determining which of the thousands of new compounds and increased cancer cure rates.
WCRF has developed collaborative research relationships with prominent pharmaceutical and biotech companies, including Genentech-Roche, Merck, Amgen, Eli Lilly, Pfizer, Genelux, Endocyte, Cetocor Ortho Biotech, Nektar Therapeutics, Abbott Laboratories, Sunesis Pharmaceuticals, and many other innovative companies. WCRF works with the research arms of these companies to choose new trial runs, design, conduct and help analyze these clinical trials.
Case reports are peer review published reports of a small number of patients with exceptional medical situations. For example, WCRF published a case report on one young woman with “incurable” recurrent widespread cervical cancer. She was treated with an ovarian cancer chemotherapy regimen and was cured. That sort of “oh my God” experience is one way major progress is made in medical research. Reporting these exceptional cases in the medical literature is key to letting the world’s researchers and physicians know about these discoveries. WCRF gets calls from physicians, researchers and patients around the world regarding its research reports.
The innovative, efficient, patient-friendly, doctor-friendly approach to research results in WCRF publishing 12-15 peer review research papers per year in prestigious journals, such as Gynecologic Oncology, International Journal of Gynecologic Cancer, Obstetrics and Gynecology and other major publications. Our publication rate is 300-400% greater per physician than the standard volume of university volume of publications.
The benchmark by which a donor can be sure that their funds are used wisely and efficiently. Cancer foundations that do not publish peer-review papers are not doing meaningful research.